Fennec Pharmaceuticals Inc.
FENC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.23 | -0.10 | 0.87 | 0.33 |
| FCF Yield | 0.57% | -1.61% | -2.57% | -0.85% |
| EV / EBITDA | -257,203.78 | -90.91 | -210.52 | -182.90 |
| Quality | ||||
| ROIC | -0.48% | -7.49% | -2.12% | -2.46% |
| Gross Margin | 94.70% | 89.98% | 95.74% | 91.56% |
| Cash Conversion Ratio | -2.34 | 1.17 | 3.71 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 43.61% | 71.68% | 112.71% | 214.03% |
| Free Cash Flow Growth | 140.50% | 14.64% | -192.94% | 33.18% |
| Safety | ||||
| Net Debt / EBITDA | 3,837.26 | -0.26 | 4.25 | 8.02 |
| Interest Coverage | -0.32 | -4.43 | -1.34 | -0.97 |
| Efficiency | ||||
| Inventory Turnover | 0.27 | 0.44 | 0.27 | 0.63 |
| Cash Conversion Cycle | -322.13 | -184.89 | -776.35 | -147.09 |